(secondQuint)Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer.

 Patient Population: Thoracic esophageal cancer able to tolerate tri-modality therapy; Clinical stage T3-4, N0-1, M0 Scheme: Patients are randomized to 2 arms: Arm A: Paclitaxel/carboplatin and concurrent radiation (50.

4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.

 Arm B: Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.

4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.

.

 Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer@highlight

This is a prospective Randomized Phase II Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and carboplatin) for Esophageal Cancer.

